LVV

2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron

Retrieved on: 
Monday, April 1, 2024
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, LVV, BCMA, Patient, Sale, Multiple myeloma, BMS, Cancer, Bristol Myers Squibb, APA, Pharmaceutical industry

(Nasdaq: TSVT), announced today the completion of the asset purchase agreement (“APA”) by Regeneron Pharmaceuticals, Inc.

Key Points: 
  • (Nasdaq: TSVT), announced today the completion of the asset purchase agreement (“APA”) by Regeneron Pharmaceuticals, Inc.
  • Under the terms of the APA, Regeneron has acquired all oncology and autoimmune research and development programs and has hired approximately 160 employees from 2seventy bio as part of their newly launched cell medicines business.
  • “With the completion of the Regeneron transaction, 2seventy officially embarks on our new strategic path forward to focus on unlocking the value of Abecma,” said Chip Baird, CEO.
  • With the resulting cost savings from reduced headcount and the sale of the pipeline assets to Regeneron, 2seventy bio has extended cash runway beyond 2027.

EurekaBio Completes $40 Million Series B+ Financing to Advance EuLV™ Lentiviral Vector Production System

Retrieved on: 
Thursday, March 7, 2024
Plasmid, Investment, Growth, Transfection, Series, LVV, CGT, Patient, AAV, Vaccine

SHENZHEN, China, March 7, 2024 /PRNewswire/ -- Shenzhen Eureka Biotechnology Co., Limited (EurekaBio), a leading upstream supplier in the cell and gene therapy field, announced the completion of its Series B+ financing, exceeding $40 million. The financing was led by YUEXIU INDUSTRIAL FUND, with participation from numerous well-known Chinese funds, as well as follow-on investments from U.S. funds.

Key Points: 
  • EurekaBio's core innovation lies in the EuLV™ Lentiviral Vector Production System, a cutting-edge technology that transforms the large-scale production of lentiviral vectors using stable cell lines and a serum-free suspension system.
  • In contrast to traditional transient transfection production methods, the EuLV™ Lentiviral Vector Production System eliminates the necessity for plasmids, resulting in cost savings related to plasmid production and streamlining the overall production process.
  • Moreover, the EuLV™ system adopts a high-density suspension culture, which substantially increases unit titer levels, reduces production batches and associated costs and meets the requirements of large-scale lentiviral vector production.
  • The EuLV™ system presents a next-generation solution for lentiviral vector production to power cell and gene therapies, and is also well positioned for global adoption.

Genezen Enters Licensing Agreement with CSL for the Cytegrity™ Stable Lentivirus Production System

Retrieved on: 
Wednesday, February 21, 2024
Biotechnology, CSL, GMP, CDMO, Safety, LVV, Patient, CSO, Immortalised cell line, Vaccine

FISHERS, Ind. and BOSTON, Feb. 21, 2024 /PRNewswire/ -- Genezen, a leading cell and gene therapy Contract Development and Manufacturing Organization (CDMO), today announced licensing of the Cytegrity™ proprietary ­­­­stable production system from biotechnology leader CSL.

Key Points: 
  • Licensing of a proven stable producer system for lentiviral vector production represents a significant investment in next-generation technology for Genezen, offering its clients immediate access to cutting edge technology for stable and scalable high-titer clinical lentivirus production.
  • and BOSTON, Feb. 21, 2024 /PRNewswire/ -- Genezen, a leading cell and gene therapy Contract Development and Manufacturing Organization (CDMO), today announced licensing of the Cytegrity™ proprietary ­­­­stable production system from biotechnology leader CSL.
  • Cytegrity™ is an advanced inducible stable producer technology designed for the production of lentiviral vectors (LVVs).
  • We have significant, hands-on experience scaling up and producing LVV using this stable production system at our GMP vector facility in Fishers, Indiana.

2seventy bio Announces New Strategic Path Forward

Retrieved on: 
Tuesday, January 30, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Partnership, ODAC, Multiple myeloma, Growth, Bristol Myers Squibb, CMO, Science, Research, Trial of the century, GV (company), Patient, AML, BMS, BCMA, LVV, Ovarian cancer, MUC16, Physician, Autoimmunity, APA, TS, PDUFA, Webcast, Workforce, Johnson & Johnson, Management

2seventy bio, in partnership with Bristol Myers Squibb (BMS), is taking actions to return Abecma to commercial growth in 2024.

Key Points: 
  • 2seventy bio, in partnership with Bristol Myers Squibb (BMS), is taking actions to return Abecma to commercial growth in 2024.
  • 2seventy bio and BMS are expanding its Abecma site footprint to enable more patients to access the treatment.
  • Upon closing of the transaction with Regeneron, Chip Baird, chief operating officer, will become chief executive officer of 2seventy bio.
  • After 13 years of service on the bluebird bio and 2seventy bio Board of Directors, Dan Lynch will step down from the Board in June and will continue in an advisory role for 2seventy bio.

Charles River Launches Rep/Cap Plasmids to Streamline Adeno-Associated Viral Vector Manufacturing

Retrieved on: 
Tuesday, January 16, 2024
Health, Medical Devices, Infectious Diseases, Genetics, General Health, Pharmaceutical, Biotechnology, Miami Beach Convention Center, Senior, CRL, CMC, Regulation, Patient, CTA, LVV, DNA, AAV, Education minister, GMP, Gene, Tecmar, IND, COA, Doctor of Philosophy, Investigational New Drug, RC2, Cell, CDMO, Commercialization, Plasmid, Pharmaceutical industry

Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its off-the-shelf Rep/Cap plasmid offering, designed to streamline adeno-associated virus (AAV)-based gene therapy programs.

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its off-the-shelf Rep/Cap plasmid offering, designed to streamline adeno-associated virus (AAV)-based gene therapy programs.
  • Charles River will officially launch the off-the-shelf Rep/Cap plasmid offering during Advanced Therapies Week , January 16-19, at the Miami Beach Convention Center.
  • Join Dr. Baghirzade in the Gene Therapy Manufacturing Track as part of the Regulatory Alignment for Gene Therapy Manufacturing session to learn how to:
    Ensure alignment with phase-appropriate plasmid DNA, AAV, and lentiviral vector (LVV) manufacturing best practices
    Matthew Hewitt, B.A.
  • Charles River has significantly broadened its cell and gene therapy portfolio with several acquisitions and capacity expansions to simplify complex supply chains and meet the growing global demand for plasmid DNA, viral vector, and cell therapy services.

bluebird bio to Present New and Updated Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition

Retrieved on: 
Thursday, November 2, 2023
Health, Genetics, Other Health, General Health, Pharmaceutical, Biotechnology, Hemoglobinopathy, FDA, MSCE, PDUFA, Busulfan, Food, LVV, SCD, History, Sickle cell disease, Ronas Voe, Prescription Drug User Fee Act, Data, Children's Hospital of Philadelphia, Thalassemia, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, TDT, Max Healthcare, University of Pennsylvania, Pediatrics, Society, ASH, Priority review, Quality of life, San Diego Convention Center, Division, HRQOL, Perelman School of Medicine at the University of Pennsylvania, University, Exposition, Month, Hospital, BLA, Betibeglogene autotemcel, Pharmaceutical industry, Vaccine, Patient, Quality of life (healthcare), Safety, Hematology

The meeting will take place December 9-12, 2023 at the San Diego Convention Center and online.

Key Points: 
  • The meeting will take place December 9-12, 2023 at the San Diego Convention Center and online.
  • lovo-cel treatment regimen largely reflects known side effects of hematopoietic stem cell collection and busulfan conditioning regimen and underlying sickle cell disease.
  • Updated iron management outcomes demonstrating sustained improvements in iron burden, with the majority of patients able to stop iron chelation therapy, will also be presented.
  • Safety of beti-cel treatment largely reflects the known side effects of hematopoietic stem cell collection and busulfan conditioning regimen.

Genezen Secures $18.5 Million in Growth Equity to Expand Viral Vector Development and Manufacturing Capabilities

Retrieved on: 
Thursday, November 2, 2023
GMP, Growth, CDMO, Patient, AAV, General partnership, Partnership, LVV, Vaccine, Fisher

FISHERS, Ind. and BOSTON, Nov. 2, 2023 /PRNewswire/ -- Genezen, a leading cell and gene therapy Contract Development and Manufacturing Organization (CDMO), today announced the closing of an $18.5 million follow-on growth equity investment led by Ampersand Capital Partners. The financing will accelerate Genezen's growth trajectory in retroviral, lentiviral and adeno-associated viral (AAV) vector manufacturing and support the execution of a robust pipeline of customer projects for innovators developing groundbreaking cell and gene therapies.

Key Points: 
  • and BOSTON, Nov. 2, 2023 /PRNewswire/ -- Genezen, a leading cell and gene therapy Contract Development and Manufacturing Organization (CDMO), today announced the closing of an $18.5 million follow-on growth equity investment led by Ampersand Capital Partners.
  • The financing will accelerate Genezen's growth trajectory in retroviral, lentiviral and adeno-associated viral (AAV) vector manufacturing and support the execution of a robust pipeline of customer projects for innovators developing groundbreaking cell and gene therapies.
  • Genezen recently completed qualification of its 25,000 sq ft GMP viral vector facility in Fishers, Indiana.
  • Clients are drawn to the team's scientific expertise, and this equity financing will enable continued development and growth for Genezen."

OBiO has launched its state-of-the-art GMP production facility Intelli-M to expedite innovative and advanced therapies to patients who are in need.

Retrieved on: 
Wednesday, September 27, 2023
GMP, LVV, CGT, Gene, Research, Multimedia, AAV, Messenger, US, Running, CDMO, Patient, Cell, Plasmid, IND, Vaccine, Renewable energy

OBiO has been privileged to collaborate with over 110 esteemed global clients.

Key Points: 
  • OBiO has been privileged to collaborate with over 110 esteemed global clients.
  • Meanwhile，this purpose-built facility, spanning 828,000+ square feet and equipped with 29 production lines, has officially commenced operations.
  • OBiO Technology CEO Guodong Jia said: "Currently, this industry is in a rapid development phase, characterized by intricate process development and challenging large-scale production requirements.
  • By leveraging cutting-edge and proprietary technologies, this facility expands OBIO's process development and GMP manufacturing capabilities.

Charles River Unveils Lentivation Platform to Expedite LVV-based Gene Therapy Manufacturing

Retrieved on: 
Tuesday, September 26, 2023
Biotechnology, Technology, Manufacturing, Health, General Health, Pharmaceutical, Medical Devices, Research, Other Manufacturing, Software, Science, GMP, DNA, LVV, OTS, Transfection, Doctor of Philosophy, AAV, EDT, ATMP, CDMO, Patient, CRL, NYSE, Vaccine, Pharmaceutical industry, MD

Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its lentiviral vector (LVV) manufacturing platform, Lentivation™ .

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its lentiviral vector (LVV) manufacturing platform, Lentivation™ .
  • The addition of Lentivation follows the launch of Charles River’s OTS LVV packaging and AAV pHelper plasmids, and eXpDNA™ plasmid manufacturing platform, aimed at supporting both LVV-based and AAV-based gene therapy programs.
  • Lentivation also complements the nAAVigation™ platform announced previously, further bolstering Charles River’s cell and gene therapy manufacturing capabilities.
  • The proven platform builds on Charles River’s established capabilities and processes, fine-tuned over decades spent successfully supporting advanced therapy clients.” - Beth Tebeau, Site Director, Rockville, MD, Charles River

AGC Biologics Offers Guaranteed Delivery of at least 1e11 TU of LVV Material in Nine Months

Retrieved on: 
Thursday, September 14, 2023
Stem Cells, Biotechnology, Other Health, Health, Pharmaceutical, Oncology, Other Science, Research, Infectious Diseases, Science, Clinical Trials, GMP, DNA, LVV, Plasmid, Gene-centered view of evolution, Hook effect, AGC, AAV, CDMO, Patient, Cell, PPQ, Pharmaceutical industry, Vaccine

The AGCellerate LVV offering guarantees developers 1e11 total transduction units (TU) of LVV material in nine months.

Key Points: 
  • The AGCellerate LVV offering guarantees developers 1e11 total transduction units (TU) of LVV material in nine months.
  • “AGC Biologics already has one commercially approved LVV in the market and successfully concluded the PPQ campaigns of five other LVV projects.
  • By utilizing our proven platform process, AGCellerate for LVV supports developers seeking quality material on an accelerated timeline.”
    The AGCellerate LVV offering is supported by AGC Biologics’ proprietary ProntoLVV™ Platform, which offers a standardized process for full-scale development and manufacturing of viral vectors.
  • AGC’s AGCellerate program offers support for monoclonal antibodies (mAbs), LVV material, plasmid DNA (pDNA) and adeno-associated viral vectors (AAV).